Skip to main content
. 2016 Dec 28;8(4):6970–6983. doi: 10.18632/oncotarget.14344

Table 5. miR-181c expression in the validation study compared with and without recurrence.

Patients with recurrencen=7, (%) Patients without recurrencen=50, (%) Chi-square 3 yearRFS rate (%) log-rank
P value P value
miR-181c 0.001 < 0.001
 High (n=13) 5 (71.4) 8 (16.0) 61.5
 Low (n=44) 2 (28.6) 42 (84.0) 95.2